Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00498979 · ClinicalTrials.gov registry record · Phase 1

Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers

A Phase 1 study of Stage IV Melanoma, sponsored by Case Comprehensive Cancer Center.

Completed
Registry status
Phase 1
Development phase
22
Enrollment target
1
Study location

NCT00498979 is a Phase 1 study of Stage IV Melanoma that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 22 participants, below the 45-participant average among 13 other Stage IV Melanoma trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00498979, a Phase 1 study of Stage IV Melanoma, has completed, sponsored by Case Comprehensive Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Sodium stibogluconate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma and other cancers. Drugs used in chemotherapy, such as cisplatin, vinblastine, and dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sodium stibogluconate and interferon alfa-2b together with combination chemotherapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of sodium stibogluconate when given together with interferon alfa-2b, cisplatin, vinblastine, and dacarbazine in treating patients with advanced melanoma or other cancer.

Conditions Studied

Stage IV Melanoma

Interventions

  • DRUG cisplatin
  • DRUG vinblastine
  • DRUG dacarbazine
  • BIOLOGICAL recombinant interferon alfa-2b
  • DRUG sodium stibogluconate

Study Locations (1)

Ohio

  • Cleveland Clinic Taussig Institute, Case Comprehensive Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2007-05
Est. Completion 2012-01
Phase Phase 1

Sponsor

Case Comprehensive Cancer Center

407 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00498979

The ClinicalTrials.gov registry entry for NCT00498979 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 45-participant average among 13 other Stage IV Melanoma trials with a reported enrollment target (51% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Stage IV Melanoma appearing as the primary indexed condition, and to 5 interventions - of which cisplatin is the first listed.

NCT00498979 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT00498979 about?

NCT00498979 is a clinical study titled "Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers". RATIONALE: Sodium stibogluconate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma and other cancers. Drugs used in chemotherapy, such as cisplatin, vinblastine, a...

What is the current status of trial NCT00498979?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2007-05. Estimated completion is 2012-01.

What conditions does trial NCT00498979 study?

This clinical trial studies the following conditions: Stage IV Melanoma.

What interventions are being tested in trial NCT00498979?

The interventions under investigation include: cisplatin (DRUG), vinblastine (DRUG), dacarbazine (DRUG), recombinant interferon alfa-2b (BIOLOGICAL), sodium stibogluconate (DRUG).

Who is sponsoring clinical trial NCT00498979?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00498979 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IV Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stage IV Melanoma

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.